Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Jon Holmlund
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Procedures
Concepts & Ideas
Genes & Molecular Sequences
Sign-in to see full Profile
Network (preview)
10
Dorr, Andrew
10
Geary, Richard
8
Kwoh, Jesse
6
Monia, Brett
6
Dorr, Andrew
3
Sikic, Branimir
3
Nemunaitis, John
3
Halsey, Joanne
3
Fisher, George
2
Advani, Ranjana
2
Johnston, JF
2
Mani, Sridhar
2
Lum, Bert
2
O'Dwyer, Peter
2
Oza, Amit
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Jon Holmlund (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2005: Advani Ranjana; Lum Bert L; Fisher George A; Halsey Joanne; Geary Richard S; Holmlund Jon T; Kwoh T Jesse; Dorr F Andrew; Sikic Branimir I
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
Investigational new drugs 2005;23(5):467-77.
-
2005: Grossman Stuart A; Alavi Jane B; Supko Jeffrey G; Carson Kathryn A; Priet Regina; Dorr F Andrew; Grundy John S; Holmlund Jon T
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
Neuro-oncology 2005;7(1):32-40.
-
2004: Marshall John L; Eisenberg Steven G; Johnson Michael D; Hanfelt John; Dorr F Andrew; El-Ashry Dorraya; Oberst Michael; Fuxman Yair; Holmlund Jon; Malik Shakun
A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.
Clinical colorectal cancer 2004;4(4):268-74.
-
2004: Villalona-Calero Miguel A; Ritch Paul; Figueroa Jose A; Otterson Gregory A; Belt Robert; Dow Edward; George Sebastian; Leonardo James; McCachren Spence; Miller G Lance; Modiano Manuel; Valdivieso Manuel; Geary Richard; Oliver Jennifer W; Holmlund Jon
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6086-93.
-
2004: Rao S; Watkins D; Cunningham D; Dunlop D; Johnson P; Selby P; Hancock B W; Fegan C; Culligan D; Schey S; Morris T C M; Lissitchkov T; Oliver J W; Holmlund J T
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(9):1413-8.
-
2004: Advani Ranjana; Peethambaram Prema; Lum Bert L; Fisher George A; Hartmann Lynn; Long Harry J; Halsey Joanne; Holmlund Jon T; Dorr Andrew; Sikic Branimir I
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Cancer 2004;100(2):321-6.
-
2003: Oza A M; Elit L; Swenerton K; Faught W; Ghatage P; Carey M; McIntosh L; Dorr A; Holmlund J T; Eisenhauer E;
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
Gynecologic oncology 2003;89(1):129-33.
-
2003: Adjei Alex A; Dy Grace K; Erlichman Charles; Reid Joel M; Sloan Jeff A; Pitot Henry C; Alberts Steven R; Goldberg Richard M; Hanson Lorelei J; Atherton Pamela J; Watanabe Tanya; Geary Richard S; Holmlund Jon; Dorr F Andrew
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):115-23.
-
2002: Cripps M Christine; Figueredo Alvaro T; Oza Amit M; Taylor Marianne J; Fields Anthony L; Holmlund John T; McIntosh Lynn W; Geary Richard S; Eisenhauer Elizabeth A
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2188-92.
-
2002: Mani Sridhar; Rudin Charles M; Kunkel Katie; Holmlund Jon T; Geary Richard S; Kindler Hedy L; Dorr F Andrew; Ratain Mark J
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1042-8.
-
2001: Cunningham C C; Holmlund J T; Geary R S; Kwoh T J; Dorr A; Johnston J F; Monia B; Nemunaitis J
A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.
Cancer 2001;92(5):1265-71.
-
2001: Rudin C M; Holmlund J; Fleming G F; Mani S; Stadler W M; Schumm P; Monia B P; Johnston J F; Geary R; Yu R Z; Kwoh T J; Dorr F A; Ratain M J
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1214-20.
-
2000: Cunningham C C; Holmlund J T; Schiller J H; Geary R S; Kwoh T J; Dorr A; Nemunaitis J
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1626-31.
-
2000: Monia B P; Holmlund J; Dorr F A
Antisense approaches for the treatment of cancer.
Cancer investigation 2000;18(7):635-50.
-
1999: O'Dwyer P J; Stevenson J P; Gallagher M; Cassella A; Vasilevskaya I; Monia B P; Holmlund J; Dorr F A; Yao K S
c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3977-82.
-
1999: Yuen A R; Halsey J; Fisher G A; Holmlund J T; Geary R S; Kwoh T J; Dorr A; Sikic B I
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3357-63.
-
1999: Nemunaitis J; Holmlund J T; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh T J; Geary R; Dorr A; Von Hoff D; Eckhardt S G
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3586-95.
-
1999: Stevenson J P; Yao K S; Gallagher M; Friedland D; Mitchell E P; Cassella A; Monia B; Kwoh T J; Yu R; Holmlund J; Dorr F A; O'Dwyer P J
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2227-36.
-
1999: Holmlund J T; Monia B P; Kwoh T J; Dorr F A
Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Current opinion in molecular therapeutics 1999;1(3):372-85.
Sign-in to see more
